









Mercado
/
Acciones
/
nasdaq-mltx
/

MoonLake Immunotherapeutics

MLTX

53.310USD

+0.390+0.74%

Horarios del mercado （ET）Cotizaciones retrasadas 15 min

3.38BCap. mercado

PérdidaP/E TTM



MoonLake Immunotherapeutics

53.310

+0.390+0.74%

Descripción general Compañía Finanzas

Finanzas

Más Datos de MoonLake Immunotherapeutics Compañía

MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

Información de la empresa

Símbolo de cotizaciónMLTX

Nombre de la empresaMoonLake Immunotherapeutics

Fecha de salida a bolsaOct 20, 2020

Director ejecutivoDr. Jorge Santos Da Silva

Número de empleados100

Tipo de seguridadOrdinary Share

Fin del año fiscalOct 20

DirecciónDorfstrasse 29

CiudadZUG

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísSwitzerland

Código postal6300

Teléfono41415108022

Sitio Webhttps://moonlaketx.com/

Símbolo de cotizaciónMLTX

Fecha de salida a bolsaOct 20, 2020

Director ejecutivoDr. Jorge Santos Da Silva

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Kristian Reich

Chief Scientific Officer

3.08M

Dr. Jorge Santos Da Silva

Chief Executive Officer, Director

3.08M

Mr. Matthias Bodenstedt

Chief Financial Officer

616.67K

Mr. Simon Sturge

Independent Chairman of the Board

171.98K

Dr. Andrew J. Phillips

Independent Director

Dr. Atif Khan

Director - Strategic Planning and Projects

Ms. Catherine Moukheibir

Independent Director

Dr. Ramnik Xavier

Independent Director

Mr. Spike N. Loy, J.D.

Independent Director

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Kristian Reich

Chief Scientific Officer

3.08M

Dr. Jorge Santos Da Silva

Chief Executive Officer, Director

3.08M

Mr. Matthias Bodenstedt

Chief Financial Officer

616.67K

Mr. Simon Sturge

Independent Chairman of the Board

171.98K

Dr. Andrew J. Phillips

Independent Director

Dr. Atif Khan

Director - Strategic Planning and Projects

Desglose de ingresos

Sin datos

Sin datos

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: lun., 28 de jul

Accionistas

Tipos de accionistas

Accionistas

Proporción

BVF Partners L.P.

31.12%

Cormorant Asset Management, LP

13.38%

Fidelity Management & Research Company LLC

8.55%

Reich (Kristian)

4.85%

Santos da Silva (Jorge)

4.85%

Other

37.25%

Accionistas

Proporción

BVF Partners L.P.

31.12%

Cormorant Asset Management, LP

13.38%

Fidelity Management & Research Company LLC

8.55%

Reich (Kristian)

4.85%

Santos da Silva (Jorge)

4.85%

Other

37.25%

Tipos de accionistas

Accionistas

Proporción

Hedge Fund

52.91%

Investment Advisor

20.80%

Investment Advisor/Hedge Fund

18.92%

Individual Investor

10.94%

Corporation

4.39%

Research Firm

2.38%

Venture Capital

1.46%

Pension Fund

0.08%

Bank and Trust

0.07%

Participación institucional

Actualizado: mar., 1 de jul

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q2

325

71.13M

112.06%

-8.47M

2025Q1

329

71.47M

112.59%

-8.98M

2024Q4

308

74.57M

117.86%

+1.09M

2024Q3

292

73.42M

116.42%

+551.38K

2024Q2

282

72.21M

114.78%

+1.82M

2024Q1

274

70.82M

112.58%

-306.27K

2023Q4

260

64.82M

107.09%

-2.17M

2023Q3

219

60.33M

114.64%

-5.55M

2023Q2

175

60.28M

100.54%

+9.44M

2023Q1

123

42.29M

108.00%

-6.15M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

BVF Partners L.P.

19.75M

31.12%

Mar 31, 2025

Cormorant Asset Management, LP

8.49M

13.38%

Mar 31, 2025

Fidelity Management & Research Company LLC

5.43M

8.55%

-59.34K

-1.08%

Mar 31, 2025

Reich (Kristian)

3.08M

4.85%

Mar 15, 2025

Santos da Silva (Jorge)

3.08M

4.85%

Mar 15, 2025

T. Rowe Price Associates, Inc.

2.97M

4.69%

-369.81K

-11.06%

Mar 31, 2025

MoonLake Immunotherapeutics AG

2.79M

4.39%

+2.69M

+2715.67%

Dec 31, 2023

Avoro Capital Advisors LLC

2.77M

4.36%

Mar 31, 2025

Citadel Advisors LLC

1.48M

2.33%

-708.23K

-32.39%

Mar 31, 2025

Westfield Capital Management Company, L.P.

1.43M

2.26%

+123.15K

+9.39%

Mar 31, 2025

ETFs relacionados

Actualizado: sáb., 2 de ago

Nombre

Proporción

ALPS Medical Breakthroughs ETF

2.03%

Global X Guru Index ETF

1.53%

Harbor Health Care ETF

1.36%

Virtus LifeSci Biotech Clinical Trials ETF

0.97%

Goldman Sachs Future Health Care Equity ETF

0.63%

iShares Health Innovation Active ETF

0.13%

Nuveen ESG Small-Cap ETF

0.1%

T Rowe Price Small-Mid Cap ETF

0.1%

JPMorgan BetaBuilders US Small Cap Equity ETF

0.09%

Strive Small-Cap ETF

0.07%

ALPS Medical Breakthroughs ETF

Proporción2.03%

Global X Guru Index ETF

Proporción1.53%

Harbor Health Care ETF

Proporción1.36%

Virtus LifeSci Biotech Clinical Trials ETF

Proporción0.97%

Goldman Sachs Future Health Care Equity ETF

Proporción0.63%

iShares Health Innovation Active ETF

Proporción0.13%

Nuveen ESG Small-Cap ETF

Proporción0.1%

T Rowe Price Small-Mid Cap ETF

Proporción0.1%

JPMorgan BetaBuilders US Small Cap Equity ETF

Proporción0.09%

Strive Small-Cap ETF

Proporción0.07%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones

Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

KeyAI

